Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27792226 | 0.87 | KDM4E (0.53) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL21994382 | 0.87 | KDM4E (0.44) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL896633 | 0.87 | KDM4E (0.51) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL13469244 | 0.86 | KDM4E (0.58) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL3481132 | 0.86 | HPGD (0.53) | KDM4ECA1CA2HPGDCYP3A4 | |
| SCHEMBL14441468 | 0.86 | KDM4E (0.48) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL31444122 | 0.85 | CA12 (0.61) | KDM4ECYP1A2CYP2C19CYP2C9CA1 | |
| SCHEMBL10112008 | 0.85 | ALDH1A1 (0.54) | KDM4ECYP1A2HPGDCYP3A4KMT2A | |
| SCHEMBL7073236 | 0.85 | SMN1; SMN2 (0.54) | KDM4EHPGDKMT2AHSD17B10GAA | |
| SCHEMBL3230860 | 0.85 | KDM4E (0.61) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4598933-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | Allorion Therapeutics Inc (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4577537-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-120091998-A | Substituted bicyclic rings as HSET inhibitors | 默克专利股份公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119968377-A | Phosphoramidate compounds and uses thereof | 安锐生物医药公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4426681-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2024-09-11 | — | — | EP | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024078392-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024042007-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2006138549-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| WO-2006049764-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2006-05-11 | — | — | WO | disclosed |
| EP-1615633-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-01-18 | — | — | EP | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | KDM4E 240/4885CYP1A2 4592/4885CYP2C19 4819/4885 |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | KDM4E 1536/4885CYP1A2 32/4885CYP2C19 115/4885 |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | HTR1A, HTR7, HTR3A | KDM4E 3279/4885CYP1A2 605/4885CYP2C19 622/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | KDM4E 628/4885CYP1A2 2456/4885CYP2C19 3978/4885 |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | KDM4E 4265/4885CYP1A2 1535/4885CYP2C19 1883/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | KDM4E 3731/4885CYP1A2 1858/4885CYP2C19 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.